Shares of Vectura Group PLC (LON:VEC) have received an average rating of “Buy” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is GBX 199.29 ($2.62).

Several research firms have recently issued reports on VEC. Numis Securities Ltd reiterated a “buy” rating and issued a GBX 205 ($2.70) price objective on shares of Vectura Group PLC in a report on Thursday, October 5th. J P Morgan Chase & Co decreased their price objective on shares of Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an “overweight” rating for the company in a report on Thursday, September 21st. Citigroup Inc. decreased their price objective on shares of Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a “buy” rating for the company in a report on Monday, September 18th. Peel Hunt reiterated a “hold” rating and issued a GBX 160 ($2.10) price objective on shares of Vectura Group PLC in a report on Wednesday, September 6th. Finally, Panmure Gordon reiterated a “buy” rating on shares of Vectura Group PLC in a report on Wednesday, August 30th.

Vectura Group PLC (VEC) traded down 0.39% during midday trading on Wednesday, hitting GBX 102.00. 833,572 shares of the stock were exchanged. The stock’s market cap is GBX 692.07 million. The firm’s 50-day moving average is GBX 104.56 and its 200 day moving average is GBX 119.67. Vectura Group PLC has a 52 week low of GBX 88.90 and a 52 week high of GBX 166.97.

ILLEGAL ACTIVITY WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/11/vectura-group-plc-vec-receives-average-rating-of-buy-from-analysts.html.

In other Vectura Group PLC news, insider Bruno Angelici bought 70,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was acquired at an average cost of GBX 99 ($1.30) per share, with a total value of £69,300 ($91,112.28). Also, insider Andrew Derodra bought 82,000 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were acquired at an average cost of GBX 90 ($1.18) per share, with a total value of £73,800 ($97,028.66). Over the last three months, insiders have purchased 152,435 shares of company stock valued at $14,354,889.

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.